Ann: Pancreatic cancer clinical study update, page-19

Martin Rogers may well be the very reason this company has over-hyped its science and over-promised it's progress. It is his signature play. You can sift through various wreckages of his past company appointments just as I did.
He is not sophisticated enough to really understand the complexity of taking a drug or medical product through the regulatory hoops - he plays a short game of hype/raise capital/increase share price /exit usually leaving a product with the reality of a long drawn out process to reach a commercial position or even no chance of obtaining this.
He will pop up again and do the same in another space. If you are lucky enough to get in at the start take a quick road and sell early. If you want a truly inciteful and committed management team - look elsewhere.
Until Australian biomedical companies learn to avoid such a scurge the industry as a whole will look more ".com" than long term scientific investment.
Oncosil are now in the position of having a very long haul to prove the product scientifically and then look to commercialise. Ground hog day again for Mr Rogers

Tyremen